Willie C. Bogan Net Worth

The estimated Net Worth of Willie C. Bogan is at least 17.3 千$ dollars as of 29 June 2020. Willie Bogan owns over 7,500 units of PolarityTE Inc stock worth over 17,349$ and over the last 6 years Willie sold PTE stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Willie Bogan PTE stock SEC Form 4 insiders trading

Willie has made over 2 trades of the PolarityTE Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Willie exercised 7,500 units of PTE stock worth 1,800$ on 29 June 2020.

The largest trade Willie's ever made was exercising 7,500 units of PolarityTE Inc stock on 29 June 2020 worth over 1,800$. On average, Willie trades about 1,667 units every 20 days since 2018. As of 29 June 2020 Willie still owns at least 72,289 units of PolarityTE Inc stock.

You can see the complete history of Willie Bogan stock trades at the bottom of the page.

What's Willie Bogan's mailing address?

Willie's mailing address filed with the SEC is 1960 S 4250 W, Salt Lake City, UT 84104, USA.

Insiders trading at PolarityTE Inc

Over the last 6 years, insiders at PolarityTE Inc have traded over 998,958$ worth of PolarityTE Inc stock and bought 381,180 units worth 1,230,731$ . The most active insiders traders include Steve Gorlin、Peter A Cohen、Paul Elliot Mann. On average, PolarityTE Inc executives and independent directors trade stock every 21 days with the average trade being worth of 3,753$. The most recent stock trade was executed by Chris Nolet on 12 January 2023, trading 36,497 units of PTE stock currently worth 8,759$.

What does PolarityTE Inc do?

polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients'​ own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™

Complete history of Willie Bogan stock trades at PolarityTE Inc

PolarityTE Inc executives and stock owners

PolarityTE Inc executives and other stock owners filed with the SEC include:

• Richard Hague,
  Pres & CEO
• Cameron J. Hoyler,
  Gen. Counsel, Sec. and Exec. VP of Corp. Devel. & Strategy
• Daniel Gasiorowski,
  Investor Relations Contact Officer
• Wladyslaw Zmuda,
  Member of the Supervisory Board
• Michal Zadlo,
  Member of the Supervisory Board
• Beata Sobocinska,
  Member of the Supervisory Board
• Kamila Krawiec,
  Member of the Supervisory Board
• Michal Herominski,
  Member of the Supervisory Board
• Patryk Gall,
  Member of the Supervisory Board
• Emil Cybulski,
  Member of the Supervisory Board
• Pawel Cieslik,
  Member of the Supervisory Board
• Maria Biernacik-Bankowska,
  Member of the Supervisory Board
• Agnieszka Kosno,
  Chief Accounting Officer
• Zbigniew Stawinoga,
  Chairman of the Management Board
• Rafal Markiewicz,
  Chairman of the Supervisory Board
• Mark E. Lehman J.D.,
  Chief Legal Officer
• Ryan Mathis M.D.,
  Chief Medical Officer
• Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D.,
  Sr. VP of Corp. Devel. & Pres of Contract Services
• Dr. Stephen Milner M.D., DDS, DSc, FRCSE, FACS,
  Chief Clinical Officer & Member of Clinical Advisory Board
• Alain Adam,
  VP of Sales
• Angela Ziegler,
  VP of Marketing & PR
• Rich Haerle,
  VP of Investor Relations & Strategy
• Nikolai Sopko,
  Chief Scientific Officer and VP of R&D
• Jacob Alexander Patterson,
  Chief Financial Officer
• Jacob Alexander Patterson,
  Chief Financial Officer
• Chris Nolet,
  Director
• Jessica Xiaolin Shen,
  Director
• David B Seaburg,
  Director
• Jon Mogford,
  Director
• Rainer M Erdtmann,
  Director
• Peter A Cohen,
  Director
• Paul Elliot Mann,
  Chief Financial Officer
• Edward Winslow Swanson,
  Chief Trans. Med. Officer
• Steve Gorlin,
  Director
• Jeffrey Hansen Dyer,
  Director
• Willie C. Bogan,
  Director
• Minnie Baylor Henry,
  Director
• Denver Lough,
  
• Richard Hague,
  Chf. Exec. Off. & Pres.
• Cameron J. Hoyler,
  Gen. Counsel & Exec. VP